Can’t bear to say goodbye to your pet? Biotech’s got you covered.

As pet ownership becomes increasingly central to modern life, a growing sector of the biotech industry is focusing on pet longevity. Companies like Loyal are currently conducting clinical trials for drugs aimed at improving metabolic health and treating age-related conditions in dogs. Beyond pharmaceuticals, the market for pet preservation has expanded to include controversial practices such as cloning and cryonics. While firms like Viagen Pets offer genetic duplication for a significant fee, and facilities like Alcor provide long-term storage for deceased animals, these technologies spark intense ethical debate. Experts note that while these services may offer comfort to grieving owners, they raise profound questions about the finality of death and the psychological impact on families. As these technologies evolve, the industry faces a complex intersection of scientific advancement, commercial opportunity, and the emotional realities of the human-animal bond.